This article was originally published in The Gray Sheet
U.S. Department of Justice initiates inquiry relating to events leading up to the firm's Oct. 5 voluntary recall of its NIR ON Ranger with SOX coronary stent delivery system ("The Gray Sheet" Oct. 12, p. 28). The company "is not aware that [DoJ] is doing anything more than gathering information," Boston states, adding "we do not understand [DoJ's] interest in this matter." Separately, Boston is the subject of a recent class action lawsuit in the U.S. District Court for Massachusetts filed by the law firm of Berger & Montague relating to improperly recorded revenues for Japan ("The Gray Sheet" Nov. 9, p. 5)
You may also be interested in...
Approval of Abbott Laboratories' Prism hepatitis B core antibody and HIV-1/2 assays likely will be delayed by FDA's finding that Abbott's Lake County, Illinois diagnostic manufacturing facility still does not comply with quality system regulations, the firm said
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.